Voxelotor Approval Status
FDA Approved: No
Generic name: voxelotor
Company: Global Blood Therapeutics, Inc.
Treatment for: Anemia, Sickle Cell
Voxelotor is an oral, HbS (sickle hemoglobin) polymerization inhibitor in development for the treatment of patients with sickle cell disease (SCD).
Development Status and FDA Approval Process for voxelotor
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.